# Australasian Gastrointestinal Pathology Society 4th Annual Scientific Meeting

27 & 28 October 2018 Clinical Education Centre, Auckland Hospital, New Zealand

www.agps.org.nz



# Pouchitis and Cuffitis A bloody mess

Sze-Lin Peng
Colorectal Surgeon

20.0.0000.00.800..


Counties Manukau District Health Board






## Ileal-pouch anal anastomosis


Proctocolectomy with J-pouch Reconstruction Stage 1






https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinical-briefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis

## Types of pouch




https://my.clevelandclinic.org/health/treatments/17379-pouch-procedure--recovery/types-of-surgeries



https://doi.org/10.1053/j.scrs.2015.09.013; http://dx.doi.org/10.1590/S2237-93632012000300009

## The anatomy of a pouch



Inflamm Bowel Dis • Volume 00, Number 00, Month 2018, British Journal of Surgery 1998, 85, 1517–1521

## Pouch function and life span

- 4-8 motions a day, 1-3 motions at night
- Continent
- Good QOL at 12 months
- Dietary modification + loperamide
- Fecal incontinence up to 40-50% in 20-30yrs
- 15% pouch failure at median 6 yrs
  - Loop ileostomy or pouch excision
  - Even higher in Crohn's disease 25-100%

## **Symptoms**

#### Surgical

- Leak
- Fistula
- Volvulus
- Efferent limb
- Stricture/ stenosis

Bloody motions Fever

Frequency

Tenesmus

Pain

Incontinence

Vaginal/ perianal discharge
Weight loss

#### Inflammatory

- Cuffitis
- Pouchitis
- Secondary pouchitis

#### Neoplastic

Pouch cancer


#### **Functional**

• Irritable pouch syndrome

## Clinical approach

- History
  - Review previous scopes, histology and operation notes
  - Toxins
- Examination+ Biopsies
  - Endoscopy
  - Examination under anaesthesia
- Investigations
  - Bloods
  - MRI/CT
  - Stool cultures

## Standardised pouchoscopy report



Inflamm Bowel Dis • Volume 00, Number 00, Month 2018

#### **Pouchitis**

- Most common long term complication
- Cumulative incidence 20-50% (1 5 yrs)
- 40% occur in the 1<sup>st</sup> 12 months post ileostomy closure
- 40% single episode only
- 5-20% end up with refractory disease
- Risk factors
  - Extensive UC, PSC, pANCA +ve, non-smoker, young, regular NSAIDs, obesity, backwash ileitis, genetic polymorphisms

## Pathogenesis

#### Idiopathic

- Gut microbiota
- Host immune response
- Genetic

## Secondary (20-30%)

- Crohn's disease
- Radiation
- Ischaemia
- Infection

# Pouch disease activity index (PDAI)

Histology useful in clinical practice

- Detection of specific pathogens (such as CMV, Candida)
- Granulomas
- Ischemia
- Mucosal prolapse
- Dysplasia

Chronic histological may reflect 'normal' adaptive changes to stasis

Criteria	Score
Clinical	
Stool frequency	
Usual postoperative stool frequency	0
1-2 stool/d > postoperative usual	1
3 or more stool/d > postoperative usual	2
Rectal bleeding	
None or rare	0
Present daily	1
Fecal urgency or abdominal cramps	
None	0
Occasional	1
Usual	2
Fever (temperature > 37.8 °C)	
Absent	0
Present	1
Endoscopic findings	
Edema	1
Granularity	1
Friability	1
Loss of vascular pattern	1
Mucous exudates	1
Illogotion	1
Histological findings - acute histological inflammation	
Polymorphonuclear leucocyte infiltration	
Mild	1
Moderate without crypt abscess	2
Severe with crypt abscess	3
Ulceration per low-power field (mean)	
< 25%/25%-50%/> 50%	1/2/3
Total pouchitis disease activity index (max 18) pouchitis ≥ 7	

## Classification of pouchitis

Duration

- acute (< 4 weeks)</li>
- Relapsing (≥3 acute episodes in 12 months)
- chronic (≥ 4 weeks)

Antibiotic response

- Responsive
- Dependent
- Refractory


Cause

- Idiopathic
- Secondary

#### **Treatment**

- Antibiotics initial treatment
  - Ciprofloxacin 500mg BD or Metronidazole 400mg TDS po 14 days
- <a href="http://www.e-guide.ecco-ibd.eu/algorithm/pouchitis">http://www.e-guide.ecco-ibd.eu/algorithm/pouchitis</a>

- Escalating therapies (budesonide, biologics..)
  - ? Reducing pouch failure incidence
  - Crohns still leading cause of pouch failure



\* Maintenance therapy consider probiotic VSL#3 4 UK sachets daily, if mucosa normal at repeat pouchoscopy. Benefits have been described in some pouch patients with pouchitis.

#### **CMV**

- May not be always pathogenic
- Probably uncommon cause of pouchitis
- Clinical features
  - Fever
  - Prepouch ileal ulcerations
  - Immunosuppression more common

#### Histology

- Immunohistochemistry/ PCR
- Inclusion bodies not always present
- Biopsies taken from ulcers more likely to contain CMV DNA

#### Treatment


- 2-4 week course of ganciclovir
- Repeat endoscopy should be considered to confirm CMV eradication/ mucosal healing, especially when features of Crohns i.e deep mucosal ulcerations and/or prepouch ileitis

#### Prognosis

Most have normal pouch function after treatment for CMV

#### Cuffitis

- Retained columnar epithelium 1.5-2cm
- UC or UC-like inflammatory process vs
   other (ischaemia/ surgical sepsis/ dysplasia)
- Clinical
  - Can co-exist with pouchitis
  - > bloody
  - Toxic megacolon, fulminant colitis, preoperative biologic use
- Usual treatment is topical ASA, steroids  $\rightarrow \rightarrow$  biologics
  - Responsive
  - Dependent
  - Refractory up to 50% 1/3 Crohns, 1/3 surgical complications,
    - Pouch failure around 10%



## Summary

- Pouchitis and cuffitis are challenging conditions to diagnose and treat
- 1<sup>st</sup> line rx for pouchitis = antibiotics
- 1<sup>st</sup> line rx for cuffitis = immunomodulators
- Multidisciplinary approach essential
  - Surgical anatomy
  - Complex medical pathogenesis
  - Balance with function and quality of life